Key result
Rifabutin accelerates DOAC metabolism via CYP3A4 and P-gp induction, risking lower drug levels and thrombosis.
Why the study?
Rifabutin induces CYP3A4 and P-glycoprotein, which can increase the metabolism of direct oral anticoagulants (DOACs), reduce their plasma concentrations, potentially decrease their anticoagulant effect, and increase thrombosis risk.
Answers are grounded in this paper and cite their sources.
Single-centre rifabutin-DOAC data remain hypothesis-generating; leaves open need for prospective interaction studies before practice change.
Rifabutin is a moderate inducer of cytochrome P450 enzymes (CYP3A4) and a weak inducer of P-glycoprotein. Rifabutin can lead to increased metabolism of direct oral anticoagulants (DOACs), reducing their plasma concentrations, potentially decreasing their anticoagulant effect and increased thrombosis risk.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question. Rifabutin increases the metabolism of direct oral anticoagulants via CYP3A4 and P-glycoprotein induction, potentially reducing plasma levels and increasing thrombosis risk.
Synapse has enriched 10 related papers. Consider them for comparative context: